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Regional mortality differences in 
end-stage renal disease: How far 
can observational studies take us?
CP Kovesdy1
The survival of patients with ESRD living in various geographic regions 
is strikingly different. Efforts to determine the reasons behind this 
observation have been hampered by difficulties in adjusting for many 
characteristics that are inherently different in patient populations living 
on different continents. The mortality rate for the general population 
in a given region could be used to adjust for risk factors that would be 
otherwise difficult to quantify.
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Geographical diff erences in the mortal-
ity rate of patients with end-stage renal 
disease (ESRD) have been described for 
more than a decade. In a study by Held 
et al.,1 the risk of mortality for patients 
on dialysis in the United States was 15% 
higher than the risk in Europe and 33% 
higher than that in Japan. Th e nephrol-
ogy community received this observation 
with great interest, as it held the promise 
of identifying modifi able factors associ-
ated with mortality in ESRD. There is 
great variability in ESRD practice patterns 
across diff erent continents, even though 
randomized controlled trials underlying 
these patterns are scarce. It thus seemed 
plausible to speculate that the diff erent 
ways we treat our patients might be at 
least in part responsible for the discrep-
ant mortality rates observed. In order to 
identify modifi able factors responsible for 
mortality, one would have to account for 
all the non-modifi able diff erences between 
the studied patient populations, a diffi  cult 
task when patients are from diff erent con-
tinents. Th is was clearly a challenge in the 
study by Held et al.,1 as their data were 
obtained from diff erent reporting systems 
and contained few variables to character-
ize the patient populations studied. Th e 
Dialysis Outcomes and Practice Patterns 
Study (DOPPS) off ered the ideal remedy 
for this problem, as it uniformly recorded 
patient outcomes from dialysis units in 
Europe, Japan, and the United States, and 
it was also able to describe the character-
istics of the diff erent patient populations 
in extensive detail.2 Not unexpectedly, it 
became clear that all ESRD patients are not 
equal: racial composition in various geo-
graphical areas is obviously diff erent, and 
patients in the United States are older and 
have a higher burden of comorbidities.3 
Detailed adjustment for this heterogeneity 
alleviated somewhat the transcontinental 
mortality gap, but the diff erence remained 
signifi cant nevertheless, again suggesting 
that variability in individual patient char-
acteristics alone is not suffi  cient to explain 
the observed geographical diversity.3
Another seemingly plausible, yet very 
diffi  cult-to-quantify, factor impacting 
on regional death-rate diff erences is the 
eff ect on mortality imparted by the sum 
of all the geographical, environmental, 
cultural, and socioeconomic eff ects that 
are unique to any given area. Diff erences 
in genetics, income level, diet and life-
style, crime rate, access to health care, or 
air quality could all be important, yet it 
seems impossible to adjust for all these 
(and probably many more) individual 
factors when comparing the risk of 
mortality in patients from areas far from 
each other. Van Dijk et al.4 (this issue) 
off er a simple and elegant solution to this 
problem: they used general population 
mortality rates as surrogate adjustment 
for a host of diffi  cult-to-measure factors, 
assuming that all or most of these factors 
have a similar impact on people living 
in the same area, including patients with 
ESRD. Th e authors compared mortal-
ity rates in patients with ESRD and in 
the general population across a north–
south divide in Europe and showed that 
general population mortality differ-
ence accounted for 26% of the regional 
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mortality diff erence in ESRD. Detailed 
patient characteristics were not available 
in the study by van Dijk et al.;4 hence it 
is unclear what caused the remaining 
diff erence. Th e idea of using contrasting 
general population mortality rates as a 
backdrop when comparing ESRD mor-
tality in diff erent countries was briefl y 
explored in the original study by Held 
et al.;1 in an addendum to their article, 
the authors compared the differences 
in general population mortality with 
those recorded in the ESRD population 
in Japan, Europe, and the United States. 
General population mortality was lower 
in Japan than in the United States, but the 
diff erence was smaller than that recorded 
between the ESRD populations in the 
two countries, suggesting that some, 
but not all, of the diff erence in the ESRD 
population mortality might be attribut-
able to factors specifi c to the studied geo-
graphic locations. Interestingly, though, 
the general population mortality in the 
United States was found to be lower 
than that in Europe, thus magnifying 
rather than alleviating the diff erences 
noted between ESRD mortality rates 
in these two regions.1 A more detailed 
analysis of this kind was used by Wong 
et al.,5 who compared ESRD mortality 
in Asian Americans versus other races 
in the United States and showed that 
race-specifi c general population death 
rates explained more than half of the 
variation in mortality imparted by race. 
In this latter study, patients of diff erent 
races were not segregated in diff erent 
geographic locations (as in studies com-
paring patients from diff erent countries); 
hence the range of factors for which gen-
eral population mortality might account 
was narrowed down to race-specific 
genetic, cultural, and/or socioeconomic 
diversity. Th is study also suggested that 
the diff erences in ESRD mortality rate 
between Japan and the United States may 
not be due to practice-related factors, as 
Asian-American patients with ESRD had 
a mortality rate similar to that of their 
counterparts in Japan.
These studies suggest that general 
population mortality rate could be used 
in future studies examining outcome 
discrepancies in diff erent ESRD popula-
tions, along with detailed adjustments for 
individual patient characteristics. Some 
questions remain, though. It is unclear 
how valid such an approach would be in 
comparing large entities (such as mor-
tality in Europe versus Japan versus the 
United States), given the clearly signifi -
cant regional variations in both ESRD and 
general population mortality rates within 
these entities.3–5 It is also unclear how the 
logic of using general population mortal-
ity to alleviate the diff erences in ESRD 
mortality across continents would apply 
in the case of the United States, where 
ESRD mortality is highest (when com-
pared with those of Japan and Europe) 
and yet general population mortality is 
lower than that reported in Europe.1
At the end of the day we are still left  
with the question: what is the benefi t of 
comparing ESRD populations from dif-
ferent regions? Practice patterns are being 
monitored in the DOPPS in order to iden-
tify factors associated with survival and 
other outcomes. Th e study by van Dijk 
et al.4 has brought renewed attention to 
a tool that could enhance similar studies. 
But we must not forget that no matter how 
sophisticated our statistical methods are, 
the results of observational studies are 
mostly hypothesis-generating and can-
not serve as ultimate proof of causality. 
Th ey are at the same time indispensable 
to provide ideas that are worth exploring 
in randomized controlled trials.
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Weighing in on fistula failure
BS Dixon1
Obesity, though not commonly reported as a cause of fistula failure, may influence 
fistula survival by making it difficult to cannulate the vein and possibly by releasing 
adipokines, such as interleukin-6, tumor necrosis factor-α, plasminogen activator 
inhibitor-1, or adiponectin, that modulate the development of neointimal hyperpla-
sia and thrombosis leading to fistula failure.
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Once established, an autogenous arterio-
venous fi stula has the lowest failure rate 
and fewest complications of any vascu-
lar access used for hemodialysis. The 
mortality rate and annual cost are also 
lower for patients with an arteriovenous 
fi stula compared with patients undergo-
ing hemodialysis using an arteriovenous 
graft  or central venous catheter. No rand-
omized trial comparing diff erent modes of 
vascular access has been done to exclude 
the possible confounding eff ect of selec-
tion bias. Nonetheless, it is likely that the 
chronic infl ammatory eff ects and infec-
tion risk of graft s and catheters account 
for much of the diff erence in complica-
tions, costs, and survival. Encouragingly, 
through the efforts of the Fistula First 
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